Trial and error in clinical studies: lessons from ATAMS

Lancet Neurol. 2014 Apr;13(4):340-1. doi: 10.1016/S1474-4422(14)70050-X. Epub 2014 Mar 6.

Authors

Fred Lühder¹, Ralf Gold²

Affiliations

¹ Department of Neuroimmunology, Institute for Multiple Sclerosis Research, The Hertie Foundation, Göttingen, Germany; Max Planck Institute for Experimental Medicine, University of Göttingen Medical School, Göttingen, Germany.
² Department of Neurology, St Josef-Hospital, Ruhr-University Bochum, Bochum 44791, Germany. Electronic address: ralf.gold@ruhr-uni-bochum.de.

PMID: 24613348
DOI: 10.1016/S1474-4422(14)70050-X

No abstract available

Publication types

Comment

MeSH terms

Female
Humans
Male
Multiple Sclerosis, Relapsing-Remitting / drug therapy*
Recombinant Fusion Proteins / administration & dosage*

Substances

Recombinant Fusion Proteins
TACI receptor-IgG Fc fragment fusion protein